Navigation Links
Drop in Breast Cancer Among White Women May Have Stalled
Date:2/28/2011

MONDAY, Feb. 28 (HealthDay News) -- Many American women abandoned hormone replacement therapy after a 2002 study found the treatment was tied to higher breast cancer risk. A sharp drop in breast cancer incidence among whites was observed soon after.

However, a new study suggests that the 2002-2003 decline in breast cancer incidence among white women did not continue through 2007.

The data suggests that the drop in breast cancers linked to women abandoning hormone replacement therapy (HRT) has now bottomed out.

Breast cancer rates among U.S. white women fell by about 7 percent between 2002 and 2003 after the release in 2002 of findings from the Women's Health Initiative study that linked HRT with an increased risk of breast cancer.

To examine whether that trend has continued, American Cancer Society and U.S. National Cancer Institute (NCI) researchers reviewed breast cancer data collected from 2000 to 2007 by NCI Surveillance, Epidemiology and End Results (SEER) registries across the country.

The analysis revealed that the sharp decline in breast cancer rates among white women that occurred between 2002 and 2003 did not continue between 2003 and 2007. Instead, breast cancer rates among white women remained relatively stable from 2003 to 2007.

"Postmenopausal hormone replacement therapy certainly had accounted for an increase in the incidence of developing a breast cancer. The use of postmenopausal HRT had sharply declined after multiple reports proved this relationship," noted one expert, Dr. Sharon M. Rosenbaum-Smith, a breast cancer specialist and surgeon at the Comprehensive Breast Center at St. Luke's-Roosevelt Medical Center in New York City.

"As more women stop using HRT, and less women start it after reaching menopause, it would be expected that the incidence [of breast cancer] would plateau at some point," she said. "This study is promising in that it has not shown an increase in the incidence of breast cancer, and the stopping of HRT use can certainly be a contributing factor to this plateau."

The new report notes, however, that the 2002-2003 trend only showed up among white women: there was no major decrease in breast cancer rates among black and Hispanic women between 2002 and 2003, and no significant changes in breast cancer rates for those groups of women from 2003 to 2007.

According to the ACS/NCI study authors, there are a number of possible factors that could explain the leveling out of breast cancer rates among white women in recent years:

  • The decrease in HRT use after 2003 may not have been large enough to continue delaying breast cancer diagnoses.
  • The trends may reflect improved sensitivity of mammography without the influence of HRT, since HRT increases breast density and compromises the diagnostic performance of mammograms and breast biopsies.
  • Breast cancer rates may reflect the relatively stable rates of screening mammography in the United States since 2000. An increase in screening rates would have likely been associated with an increased number of breast cancer diagnoses.

The study was released online in advance of publication in a future print issue of the journal Cancer Epidemiology, Biomarkers & Prevention.

More information

The U.S. National Cancer Institute has more about menopausal hormone replacement therapy and cancer.

-- Robert Preidt

SOURCES: Sharon M. Rosenbaum-Smith, breast cancer specialist, surgeon, Comprehensive Breast Center, St. Luke's-Roosevelt Medical Center, New York City; American Cancer Society, news release, Feb. 28, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
2. Low forms of cyclin E reduce breast cancer drugs effectiveness
3. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
4. For Some Breast Cancer Patients, Shorter Radiation Works Well
5. Short-term radiation therapy successful on breast cancer
6. Few Women at High Risk for Breast Cancer Take Tamoxifen
7. Hormone May Prevent Aggressive Breast Cancer
8. MSU researcher linking breast cancer patients with alternative therapies
9. MRI May Not Add Value to Routine Breast Cancer Care
10. Breast Cancer Stats Differ Racially Despite Similar Mammogram Rates
11. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drop in Breast Cancer Among White Women May Have Stalled 
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Leading pediatric ... peers in Washington, D.C., for the 49th Congress of the International Society of ... Vice President of the Center for Cancer and Blood Disorders at Children’s ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and ... 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will ... Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph ...
(Date:10/12/2017)... ... October 12, 2017 , ... In ... taxes a year. In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, ... overseas retirement havens have extremely low property-tax rates, which contributes to the relatively ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... University of California Berkeley, and other leading institutions in announcing the launch of ... institutions to change the way animals are raised for food. , Founding members ...
(Date:10/12/2017)... ... October 12, 2017 , ... Nvision Biomedical Technologies , ... the addition of industry sales leader, Thomas (Tom) Slott, as Senior Vice President ... and sales network, direct the efforts of the surgical sales teams, manage contractual ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Sept. 28, 2017 Cohen Veterans Bioscience and ... use of wearable and home sensors for real-time monitoring ... Signal Foundation, a nonprofit organization focused on disruptive health ... an affordable analytical system to record and integrate behavioral, ... ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/18/2017)... , Sept. 18, 2017  PMD Healthcare of ... Pharmacy of Kalamazoo, Mich. , have ... service that expedites and streamlines patient and provider access ... 2.0, and wellness management services.  ... used to measure lung function for a variety of ...
Breaking Medicine Technology: